中国临床药理学杂志2024，Vol.40Issue(13)：1977-1981,5.DOI:10.13699/j.cnki.1001-6821.2024.13.027
钠-葡萄糖共转运蛋白2抑制剂治疗2型糖尿病合并射血分数保留心力衰竭的研究状况
Research status of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes mellitus with heart failure with preserved ejection fraction
摘要
Abstract
Sodium-glucose co-transporter protein 2 inhibitor(SGLT2i)has steadily demonstrated benefits in the treatment of type 2 diabetes complicated with cardiovascular diseases based on evidence-based medicine,but its precise mechanism is yet unknown.We identified type 2 diabetes patients with HFpEF by searching PubMed,Web of Science,China knowledge network(CNKI),and other databases.We then summarized the pathological mechanism of HFpEF caused by type 2 diabetes.At the same time,to link to evidence-based medical,we explored the future of SGLT2i in clinical application.关键词
钠-葡萄糖共转运蛋白2抑制剂/射血分数保留型心力衰竭/2型糖尿病Key words
sodium-glucose co-transporter protein 2 inhibitor/heart failure with preserved ejection fraction/type 2 diabetes mellitus分类
药学引用本文复制引用
刘铭彦,张冰琪,李虎虎,运乃茹,范思邈,杨蓉蓉,郭瑞莹,戴永娜..钠-葡萄糖共转运蛋白2抑制剂治疗2型糖尿病合并射血分数保留心力衰竭的研究状况[J].中国临床药理学杂志,2024,40(13):1977-1981,5.基金项目
天津教委科研基金资助项目(2022ZD050) （2022ZD050）
